Sara M. Tolaney, MD, MPH, highlights updated survival and safety data seen with sacituzumab govitecan in patients with hormone receptor–positive, HER2-negative breast cancer; underscores how Trop-2 and HER2 testing is not necessarily needed for this agent in this population at this time; and shares how ongoing efforts are exploring the utilization of this agent earlier in the treatment course.
Related Keywords
Massachusetts , United States , Boston , Dana Farber Cancer Institute , Saram Tolaney , , Susanf Smith Center , Harvard Medical School , Breast Oncology , News , Breast Cancer ,
comparemela.com © 2020. All Rights Reserved.